SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Step by step instructions to Analyze Senior Insurance Contracts Really. - 2Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- 3‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- 4Overhaul Your Rest: Tips for a Serene Evening
- 5UN mission says no evidence Hezbollah rearming in southern Lebanon
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- Manual for Tracking down Spending plan Agreeable Travel Objections
- 'The Real Housewives of Rhode Island' 1st teaser trailer unveiled: Which Bachelor Nation star is part of the cast? And when does it premiere?
- Select Your Go-To Bluetooth Earphones
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- The Most Notable Design Brands of the 21st Hundred years
- A definitive Manual for Choosing Indoor Plants Ideal for Your Space
- Manual for Notorious Fragrances: Immortal Aromas
